CDH2 (Cadherin 2)

Importantly, siRNA-mediated silencing of FAM83A abolished its overexpression and inhibited EMT activation, confirming its essential role in M2-Exo-induced programming of EMT. Collectively, these findings highlight exosome-mediated immune-tumor interactions as critical drivers of EMT and the progression toward an invasive, mesenchymal-like phenotype.

Wnt pathway activator SKL2001 and inhibitor LGK974 confirmed KIF20A's role in tumor progression...ChIP-seq and promoter assays verified FOXK1's direct binding to the KIF20A promoter, activating its transcription. In conclusion, KIF20A serves as a diagnostic and prognostic biomarker promoting HCC progression via Wnt/β-catenin signaling, regulated by FOXK1, offering new therapeutic targets.

In vivo, the combination reduced tumor growth vs cisplatin alone without increasing toxicity. This is the first report that lycopene enhances cisplatin sensitivity in OSCC by coupling inhibition of MRP-1-mediated drug efflux with suppression of PI3K/Akt/mTOR and EMT/stemness-filling the gap of lycopene's synergistic mechanism with cisplatin, offering a strategy to improve therapeutic efficacy without exacerbating toxicity.

This study demonstrates the impact of microenvironmental stiffness on breast cancer cell phenotype and highlights 3D GelMA hydrogels as a platform to investigate tumour microenvironment dynamics. The findings provide insights into how matrix stiffness influences EMT and breast cancer behaviour in biomimetic settings.

Additionally, in a Dextran Sulfate Sodium (DSS)-induced colitis model combined with single-cell RNA sequencing, PUT supplementation resulted in the elimination of CXCR6+ CD8+ T cells in the colon. These findings provide new insights into how polyamine metabolism, particularly involving extracellular PUT, impairs the anti-tumor activity of CXCR6+CD8+ T cells, potentially contribut ing to CRC progression.

Notably, restoring SCN4B levels suppressed LUAD cell viability, migration and invasion in vitro, accompanied by inhibition of EMT. These findings highlighted SCN4B as a potential tumor suppressor and a promising therapeutic target for LUAD.

These findings suggest that NogoA regulates both tumour behaviour and immune remodelling in TNBC by enhancing NK cell-mediated cytotoxicity, promoting apoptosis and suppressing immune evasion pathways. Targeting the NgR1/NogoA axis may therefore represent a promising approach to strengthen NK cell-based immunotherapy, offering a novel therapeutic avenue in TNBC.

Compared with 2D cultures, 3D models better preserved and upregulated key mesenchymal markers (Vimentin and CDH2). Our findings show how these biomimetic 3D platforms better replicate sarcoid TME, offering a promising tool for comparative oncology and PV-related human cancers.

Our research reveals a novel mechanism by which ESRP2 affects BC metastasis through post-transcriptional regulation. ESRP2 may present as a promising biomarker in combating BC cell migration by targeting EMT.

This study suggests that eupatolitin suppresses, at least partially, the migration and invasion of oral cancer cells by promoting p38 phosphorylation and downregulating cathepsin S and cathepsin B expression. The findings provide experimental evidence supporting the antimetastatic potential of eupatolitin. Nonetheless, further studies are required to confirm its translational relevance.

MFN2 inhibits HSC activation and liver fibrosis by suppressing β-catenin nuclear translocation, making it a promising therapeutic target for NAFLD-related fibrosis and associated complications, such as hepatocellular carcinoma.

In vivo experiment of subcutaneous tumor formation in nude mice verified that miRNA-221/222 promoted tumor growth by targeting PHACTR4. In conclusion, miRNA-221/222 played the role of proto-oncogene in the occurrence and development of pituitary tumors by targeting PHACTR4, which provided a new target for the diagnosis and molecular treatment of pituitary adenomas.